The information requested is not available.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-08T13:54:02.043Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 April 2019 to Question 245610, how many forms of cancer have no maintenance drug available at any stage in the treatment plan.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/394", "label" : {"_value" : "Biography information for Mr Clive Betts"} } , "tablingMemberConstituency" : {"_value" : "Sheffield South East"} , "tablingMemberPrinted" : [{"_value" : "Mr Clive Betts"} ], "uin" : "249828"} , {"_about" : "http://data.parliament.uk/resources/1121970", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1121970/answer", "answerText" : {"_value" : "
Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources. NHS England is legally required to fund cancer drugs recommended in NICE technology appraisal guidance.<\/p>
The Government wants patients with cancer to be able to benefit from rapid access to effective new drugs, including for maintenance treatment. Under arrangements introduced in 2016, NICE now develops technology appraisal guidance for the NHS on all new cancer drugs. Wherever possible, NICE aims to issue draft guidance on new cancer drugs before licensing and to publish final guidance within 90 days of licensing.<\/p>
Funding is available through the Cancer Drugs Fund from the point at which NICE draft recommendations are published, or if the drug is not currently licensed, from the point of licensing. This ensures patients are able to benefit from effective new cancer drugs as quickly as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-04-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-04-25T14:05:35.397Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-04-18", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 April 2019 to Question 242692 on Cancer: Drugs, what steps the Government is taking to give timely NICE and NHS approval to enable access to maintenance medication for people with cancer.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/394", "label" : {"_value" : "Biography information for Mr Clive Betts"} } , "tablingMemberConstituency" : {"_value" : "Sheffield South East"} , "tablingMemberPrinted" : [{"_value" : "Mr Clive Betts"} ], "uin" : "245610"} , {"_about" : "http://data.parliament.uk/resources/1110551", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1110551/answer", "answerText" : {"_value" : "
The Department fully understands that maintaining access to cancer medication is vitally important to many people in this country.<\/p>
<\/p>
There is already a team within the Department that deals with medicine supply issues arising both in the community and hospitals. We have well established procedures to deal with medicine shortages, from whatever cause, and work closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.<\/p>
<\/p>
If we are aware of issues with cancer medications we work with national clinical experts to advise on management plans and ensure that appropriate information is provided to the National Health Service and specialist patient groups.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-04-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-04-15T12:58:08.703Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-04-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps is the Government taking to ensure timely access to maintenance medication for people with cancer.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/394", "label" : {"_value" : "Biography information for Mr Clive Betts"} } , "tablingMemberConstituency" : {"_value" : "Sheffield South East"} , "tablingMemberPrinted" : [{"_value" : "Mr Clive Betts"} ], "uin" : "242692"} , {"_about" : "http://data.parliament.uk/resources/1092072", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092072/answer", "answerText" : {"_value" : "
Leaving the European Union with a deal remains the Government\u2019s top priority. However, as a responsible Government we must plan for every possible outcome including \u2018no deal\u2019. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.<\/p>
<\/p>
The Government has been working closely with industry to ensure the supply of medicines, including those for cancer patients, can continue uninterrupted in the event of a \u2018no deal\u2019 EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes.<\/p>
<\/p>
In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the United Kingdom that come from, or via, the EU/European Economic Area asking them to ensure a minimum of six weeks\u2019 additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019 in the event of a \u2018no deal\u2019 EU exit.<\/p>
<\/p>
The Department has put in place a multi-layered approach to minimise any supply disruption, which includes securing, via the Department for Transport, additional roll on roll off freight capacity away from the short straits crossings to Dover and Folkestone for goods to continue to come into the UK from 29 March. In addition to asking industry to build up stockpiles in the UK ahead of 29 March we have bought extra warehouse space for the additional stock to be held in. We are supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions. We have also made changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have no deal. Finally, we are strengthening the processes and resources used to deal with shortages in the event that they do occur.<\/p>
<\/p>
We are confident that, if everyone does what they need to do, the supply of medicines and medical products will be uninterrupted.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-03-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-03-25T16:06:45.747Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-03-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he plans to prioritise patients with (a) terminal cancer and (b) cancer for the receipt of drugs in the event of medicine shortages due to the UK leaving the EU (i) without an agreement and (ii) with an agreement under which the medicine supply is restricted.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4621", "label" : {"_value" : "Biography information for Darren Jones"} } , "tablingMemberConstituency" : {"_value" : "Bristol North West"} , "tablingMemberPrinted" : [{"_value" : "Darren Jones"} ], "uin" : "234769"} , {"_about" : "http://data.parliament.uk/resources/985621", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/985621/answer", "answerText" : {"_value" : "
The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative cancer treatments and technologies at a price the National Health Service can afford. Discussions on a branded medicines voluntary agreement for 2019 onwards are ongoing and are constructive.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-10-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-10-17T13:54:42.16Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-10-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if his Department will take steps as part of the ongoing negotiations for the next Pharmaceutical Price Regulation Scheme to ensure that increasing the number of combination treatments for cancer can be considered cost-effective and made available for patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1591", "label" : {"_value" : "Biography information for Tim Farron"} } , "tablingMemberConstituency" : {"_value" : "Westmorland and Lonsdale"} , "tablingMemberPrinted" : [{"_value" : "Tim Farron"} ], "uin" : "178268"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 5, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }